We used the inhibitors bromotetramisole, L-phenylalanifle amide, and L-phenylalanine in combination to measure intestinal phosphatase in maternal serum and amniotic fluid. By using high concentrations of these inhibitors, it was possible to measure the three isoenzymes separately. We found no evidence of the presence of meconial alkaline phosphatase in the serum of the mother (six cases) after meconial passage in utero.
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It has been known for some time that certain alkaline phosphatase (EC 3.1.3.1) isoenzymes can be differentiated by use of L-amino acid inhibitors (1) . The combined use of heat stability, pH optima, and the sensitivity of liver and bone isoenzymes to L-homoarginine inhibition and of placental and intestinal isoenzymes to L-phenylalanine inhibition has been proposed as one method for "fractionation" of all clinically relevant alkaline phosphatase isoenzymes (1) .
More recently, Van Belle and his colleagues have demonstrated an extremely high sensitivity of the non-placental, non-intestinal isoenzymes of alkaline phosphatase to the inhibitors levamisole (2) and bromotetramisole (3) . It has also been found (4) that peptides can be extremely effective in discriminating between placental and intestinal phosphatases. We were attracted by the potential usefulness of the combination of bromotetramisole, L-phenylalanine amide, and L-phenylalanine for the discrimination of placental, intestinal, and "other" phosphatase isoenzymes. We were particularly motivated to test the feasibility of such an approach by the recent report (5) that meconial passage in utero led to increased activity of alkaline phosphatase in the mother's serum, an observation which those authors interpreted (5) as the result of passage of meconial phosphatase into the maternal circulation.
The passageof much meconium into amniotic fluid early in labor is a significant index of high risk to the fetus, being associated with increased intrapartum and neonatal mortality rates and an increased likelihood of depression of the infant at birth, and shows an association with other high-risk maternal conditions and other signs of fetal distress (6) . The presence of meconium in the amniotic fluid before labor is suggested by several authors as a high-risk factor, correlating with increased likelihood of fetal death or poor neonatal outcome, and the detection of meconium in amniotic fluid by amnioscopy or amniocentesis is suggested as a means of monitoring fetal well-being (7 utero is currently determined by the invasive technique of amniocentesis or the cumbersome procedure of amnioscopy, a maternal serodiagnostic test would be a distinct improvement in the determination of this clinically relevant parameter (8) .
We found that the intestinal, placental, and liver isoenzymes could be discriminated if several inhibitors were used in concentrations that inhibited specific isoenzymes by more than 90%. By sequential use of bromotetramisole alone, bromotetramisole with L-phenylalanine amide, and then bromotetramisole with phenylalanine amide and L-phenylalanine, we could fractionate "liver-bone," placental, and intestinal isoenzymes. Having done so, we were not able to find any increase in phosphatase of intestinal origin in the serum of the mother after meconial passage in utero. 
Materials and Methods

Materials
Methods
Enzyme assay was as described previously (4) . Sera and amniotic fluids were obtained from patients on the obstetrical service at Forsyth Memorial Hospital, Winston-Salem, NC. These patients were in both high-risk and low-risk categories and were undergoing amniocentesis for obstetrical indications. Informed consent was obtained, with use of a protocol approved by the clinical research practices committee of the institution.
Sera collected by venipuncture were stored at -20 #{176}C; amniotic fluids were not centrifuged and were stored frozen.
Enzyme preparations. Human placental alkaline phosphatase was homogeneous enzyme, prepared as described previously (9) . Meconial and liver alkaline phosphatases were butanol extracts of meconium and liver homogenates, prepared by mixing one volume of n-butanol with two volumes of homogenate for 2 h at 4 #{176}C, separating the aqueous layer, and dialyzing the extract against tris(hydroxymethyl)methylamine-buffered (10 mmol/L) isotonic saline, pH 7.6. Figure 1A shows the inhibition of liver, placental, and intestinal isoenzymes of alkaline phosphatase by increasing concentrations of bromotetramisole. As reported elsewhere (3), the liver enzyme is extremely sensitive to bromotetramisole inhibition, reaching a value of 97% at 100 tmol/L. At 100 Examination of the three profiles clearly shows that concentrations, per liter, of inhibitors that give near-complete inhibition are 0.1 mmol of bromotetramisole for the liver isoenzyme, 10 mmol of L-phenylalanine amide for the placental isoenzyme, and 5 mmol of L-phenylalanine for the intestinal isoenzyme. Using these inhibitors in the combinations suggested by the data of Figure 1 , we obtained the results shown in Table 1 . The liver enzyme, which was 97% inhibited by 0.1 mmolfL bromotetramisole, was not inhibited any further by addition of the other inhibitors. Identical results were obtained with enzymes from bone and lung. The placental enzyme, which was inhibited 93% by bromotetramisole plus 10 mmol of phenylalanine amide per liter, was not inhibited any more upon addition of 5 mmol of L-phenylalanine per liter. The only enzyme that showed any significant further inhibition by L-phenylalanine in the presence of the other two inhibitors was the intestinal isoenzyme. Interestingly, inhi- liter in the presence of bromotetramisole and L-phenylalanine amide is almost identical to the extent of inhibition of this isoenzyme by L-phenylalanine alone (75%) under these conditions. The inhibitor that is used at near-saturating concentrations therefore appears to be the major contributor to the degree of inhibition obtained with a given isoenzyme.
Results
From the data obtained from four assays of a given sample (a reference sample, and the combinations of inhibitors A, B, and C) it should be possible to completely fractionate phosphatases into these three types. Intestinal isoenzyme, for example, would be assayed as: (activity in B -activity in C) X (100/36) = activity of intestinal phosphatase.
Placental phosphatase would be calculated by: [activity in A -activity in B -(activity of intestinal phosphatase X 0.25)] X (100/62) = activity of placental phosphatase. Correction for the contribution of intestinal phosphatase is necessary, because this enzyme is also somewhat inhibited by L-phenylalanine amide.
Similarly, the "liver-type" phosphatase can be determined by: [activity in reference -activity in A -(activity of placental phosphatase X 0.31) -(activity of intestinal phosphatase X 0.17)] X (100/97) = activity of "liver-type" phosphatase. The simplest determination by this approach is that of the intestinal isoenzyme. To validate this approach for measurement of the intestinal component in maternal serum and amniotic fluid samples, we added meconial enzyme to samples of sera and amniotic fluid from women in the late-third trimester of pregnancy. The amounts added were equivalent to one-tenth to one-half the mean total serum phosphatase activity of women at this stage of pregnancy (see below, Table  3 ). As seen in Table 2 , the measured intestinal phosphatase activity agreed well with the sum of added intestinal phosphatase and the measured intestinal phosphatase present in the serum. The percent deviation of the measured value from the expected value was highest (18%) for 12 U of meconial phosphatase added per liter and lowest (4%) when 61 U/L was added per liter. This indicates that the test can yield a rea- is 10% of the total alkaline phosphatase, but is much more nearly accurate when this enzyme is 25% or more of the total serum phosphatase. Brandes et al. (5) claimed that the mean total phosphatase activity in the serum of patients who had meconium-stained amniotic fluid was twice that in a control group. This assay should therefore be able to detect serum meconial phosphatase if it were present in such high activities.
To test this, we used this assay to measure intestinal phosphatase in maternal serum and amniotic fluid samples (Table 3) . We divided these samples into three groups: group A, the samples that had no intestinal phosphatase in the amniotic fluid and no evidence of meconium; group B, the samples that had higher intestinal phosphatase activity in amniotic fluid and no evidence of meconium; and group C, those patients who demonstrated meconial passage in utero. In four samples, sera were obtained from women who demonstrated meconium-stained amniotic fluid upon spontaneous rupture of the fetal membranes before or during early labor. Amniotic fluid could not be obtained by amniocentesis in these patients, and for this reason, values for it are not available.
It is clear from these experiments that the presence of intestinal alkaline phosphatase in the amniotic fluid does not significantly increase the activity of this enzyme in the mother's circulation,as seen by the identity of the mean value of intestinal phosphatase in each case. A 100-fold higher concentration in some amniotic fluid samples did not significantly increase the activity of intestinal phosphatase in at CLINICAL CHEMISTRY, Vol.25,No. 7 
We did not find a significantly increased total alkaline phosphatase activity in sera from our sample of six individuals with meconial passage in utero.
Discussion
In this study, we used combinations of three inhibitors of human alkaline phosphatase that have marked specificity for the isoenzymes originating from liver and bone (bromotetramisole), placenta (L-phenylalanine amide), and intestine (L-phenylalanine) to measure intestinal phosphatase selectively in serum and the corresponding amniotic fluid.
The major difference between our approach and that of others who have used specific inhibitors is that we used high concentrationsof severalinhibitors that have selective affinity forspecific isoenzymes.This approach enables us to calculate the activities of specific isoenzymes by differences between the inhibition in the presence of a weak inhibitor and that witha strong inhibitor.
The theoreticalprinciplebehind this approach is that, if these uncompetitive inhibitors all inhibit by a similar mechanism, then the cumulative effect of several inhibitors in combination depends in each case on the ratio of inhibitor concentration to the K. Thus, at high substrate concentrations (Vmax), we expect
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Ninety-seven percent inhibition requiresthat the ratio [I]/K1 be 32:1; 93% inhibition, 13:1; and 50% inhibition, 1:1. In 0.1 mmol of bromotetramisole per liter, the liver enzyme is exposed to about 32-fold the concentration that corresponds to its K for this inhibitor. Addition of L-phenylalanine and Lphenylalanine amide at concentrations less than their K for this enzyme does not significantly change the inhibition. Similarly, in 10 mmol of L-phenylalanine amide per liter, the placentalenzyme isinhibited by 93% (13 K,), whether or not bromotetramisole ispresent at a concentration that inhibits this enzyme by 31% (0.4 K); a slight increase may be apparent if L-phenylalanine is added to give a concentration that inhibits by 75% (3K1) (1) . For intestinal phosphatase, the inhibition by 0.1 mmol/L bromotetramisole and 10 mmol/L L-phenylalanine amide (combined, 0.7 K) is lower than that in 5 rnmol/L L-phenylalanine (3K1) (1) , and so the combined inhibition is 78% (3.5 K,). We have not used the D-amino acid as a referencein this assy (1), because the use of three inhibitors in combinations, with D-amino acids as controls, would have unnecessarily complicated the assay. We have also found that, at the high concentrations of phenylalanine amide we used in these assays to discriminatethe placental enzyme, the D-isomer is slightly inhibitory. Applying this approach to measurement of intestinal-type alkaline phosphatase in amniotic fluid and serum samples, we found no significant difference in intestinal alkaline phosphatase activity in the patient's serum when there was evidence of meconial passage in utero as compared to a control group without such passage. Despite a 1000-fold difference between the activity of intestinal phosphatase in the amniotic fluid and phosphatase activity in the mother's serum, substantial amounts of meconial phosphatase did not enter the maternal circulation-not surprising, in view of the barriers preventing free exchange of these fluids.
Brandes et al. (5) observed that maternal serum alkaline phosphatase activity was increased when meconial passage in utero occurred. In our small sample of six cases of meconial passage in utero, the mean value for the mothers' serum alkaline phosphatase was the same as for our control group, and so we were unable to confirm these authors' observation. This may have been due to the small sample. We also did not find the same ratio between the total amniotic fluid alkaline phosphatase to total maternal serum alkaline phosphatase (1.0) reported by Brandes et al. (5) ; our value was 0.2 for unstained amniotic fluid. It is reasonable to suggest that the different patient populations may account for some of the differences between our findings and those of Brandes and coworkers. We can say with some assurance that there was not a significant amount of intestinal phosphatase in the sera of six women that had meconium-contaminated amniotic fluid, and this observation excludes the possibility that determination of maternal serum meconial phosphatase could be clinically useful.
The approach outlined inthis work should have some value in isoenzyme discrimination in serodiagnosis and in the study of alkaline phosphatase isoenzymes in development and in cultured cells (10) . This approach isa usefuladdition to the electrophoretic and heat-stability criteria used by others (1), especially since there may be electrophoretic differences for isoenzymes obtained from different sources. For example, this istrue forintestinal alkaline phosphatase from meconium or fetal intestine as compared with the enzyme from adult intestine (11, 12) . 
